Astrazeneca (AZN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - AstraZeneca reported revenue of $14.89 billion for the quarter ended December 2024, reflecting a 23.8% increase year-over-year and a surprise of +4.26% over the Zacks Consensus Estimate of $14.28 billion [1] - The earnings per share (EPS) for the quarter was $1.05, compared to $0.73 in the same quarter last year, although it fell short of the consensus EPS estimate of $1.07 by -1.87% [1] Financial Performance Metrics - AstraZeneca's stock has returned +6.5% over the past month, outperforming the Zacks S&P 500 composite's +2.1% change, and currently holds a Zacks Rank 3 (Hold) [3] - Key product performance includes: - Symbicort in the U.S. generated $299 million, exceeding the average estimate of $235.06 million [4] - Oncology product Tagrisso in the U.S. reported $767 million, surpassing the estimated $709.65 million [4] - Collaboration revenue totaled $815 million, significantly above the average estimate of $419.12 million, marking a +68.4% change year-over-year [4] - Oncology product Tagrisso worldwide achieved $1.70 billion, compared to the estimated $1.68 billion, representing a +20% increase year-over-year [4] - BioPharmaceuticals product Farxiga worldwide reported $1.93 billion, slightly below the estimate of $1.96 billion, but still showing a +20.4% year-over-year change [4]